Jeffrey Garrard, MD
Family Medicine · Huntsville, ALNPI 1134347495
Payments from drug & device makers
Across 312 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$940
- Novo Nordisk$550
- Pfizer$269
- Corium, LLC$234
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$170
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,76899%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 71 | $1,074 |
| AbbVie(2 entities) | 73 | $940 |
| Novo Nordisk | 33 | $550 |
| Pfizer | 17 | $269 |
| Corium, LLC | 14 | $234 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $170 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $144 |
| Bayer | 6 | $124 |
| Abbott | 6 | $122 |
| Exact Sciences | 7 | $122 |
| GSK | 7 | $116 |
| Boehringer Ingelheim | 6 | $98 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Tolmar, Inc. | 5 | $82 |
| Genentech USA, Inc. | 6 | $81 |
| Antares Pharma, Inc. | 5 | $78 |
| Axsome Therapeutics, Inc. | 4 | $59 |
| Merck | 3 | $51 |
| Assertio Therapeutics, Inc. | 3 | $39 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Bausch Health US, LLC | 2 | $30 |
| Amgen | 2 | $30 |
| AstraZeneca | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Novartis | 1 | $19 |
| Intra-sana Laboratories | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
How this compares
$4,824 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 76 | $104,743 |
| SynjardyEmpagliflozin/Metformin Hcl | 22 | $29,365 |
| OzempicSemaglutide | 11 | $22,104 |
| Colesevelam Hcl | 16 | $8,998 |
| MyrbetriqMirabegron | 13 | $6,915 |
| Pregabalin | 65 | $4,660 |
| Rosuvastatin Calcium | 241 | $4,231 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,892 |
| Omeprazole | 195 | $3,539 |
| Atorvastatin Calcium | 219 | $2,680 |
| Levothyroxine Sodium | 180 | $2,425 |
| SynthroidLevothyroxine Sodium | 26 | $2,040 |
| Gabapentin | 78 | $1,860 |
| Duloxetine Hcl | 74 | $1,676 |
| Pravastatin Sodium | 95 | $1,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,074 | $104,74376 claims |
| Boehringer IngelheimSynjardy | $98 | $29,36522 claims |
| Novo NordiskOzempic | $550 | $22,10411 claims |
| AbbVieSynthroid | $940 | $2,04026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Huntsville
- Michael CarterHuntsville$3.4M
- Randle MiddletonHuntsville$3.3M
- Timothy HowardHuntsville$3M
- Edward WittHuntsville$321K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Jeffrey GarberHuntsville$87K
- Daniel EnglertHuntsville$82K
- Jack EnglertHuntsville$37K
- Tobin FisherHuntsville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.